FULC

Equibles Rating blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.57

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −56%

below

Price vs 50-day avg −29%

below

RSI (14) 39

neutral

MACD trend Positive

52-week position 7%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +8%

trailing

6-month return −64%

trailing

YTD return −67%

this year

Relative strength −71%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $5 › 200d $8 — 200d above 50d

Institutional flow Distributing

5 of 168 funds reported for Jun 30 · net -87.7K sh shares · +2 new

Insider flow Distributing

Net -$65.6K over 90 days · 100% sells

Short interest Falling

8.29% of float · ▼ -30.9% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

168 holders — near 3-yr high, broad support

Squeeze score 35

low risk · 0–100

Fundamentals

Weak

Revenue growth −100%

Y/Y

EPS growth −638%

Y/Y

Free cash flow $-60.4M

Balance sheet $197.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 99%

annualized · 1-yr

Max drawdown −78%

past year

ATR 7.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Jul 13, 2026 Est · unconfirmed · this week

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Apr 27, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−56% Bearish

Price vs 50-day avg

−29% Bearish

RSI (14)

39 Neutral

MACD trend

Positive Bullish

52-week position

7% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $5 › 200d $8 — 200d above 50d

Institutional flow Distributing

5 of 168 funds reported for Jun 30 · net -87.7K sh shares · +2 new

Insider flow Distributing

Net -$65.6K over 90 days · 100% sells

Short interest Falling

8.29% of float · ▼ -30.9% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

168 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $3 Now $4 · 7% 52-wk high $16

vs 200-day avg -56% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
cash, cash equivalents, and marketable securities	$333.3M	first quarter of 2026	—
HbF at baseline	7.1%	Phase Ib PIONEER trial call	—
HbF at week 12	19.3%	Phase Ib PIONEER trial call	—
patients with no VOCs during treatment period	7	Phase Ib PIONEER trial call	—
total patients evaluated for VOCs	12	Phase Ib PIONEER trial call	—
Mean absolute HbF increase from baseline at Week 12 (20 mg cohort)	12.2%	PIONEER Phase 1b 20 mg cohort, Week 12	—
Net proceeds from December 2025 public offering	$164.2M	December 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FULC Fulcrum Therapeutics, Inc. this stock	$239.21M	-67.0%	-100.0%	—	8.3%
ONC BeOne Medicines Ltd.	$437.67B	-0.6%	+22179.2%	890.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$126.01B	+9.9%	+46.2%	29.5	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$70.03B	-14.0%	+20.8%	16.3	3.2%
ARGX Argenx SE	$56.84B	+8.8%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

168

% held: 107.7%
Reported: 5 of 168
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

154

View

Short & Settlement

Short Interest Falling

Shares short

5.5M

Days to cover: 1.0d
Change: -2.5M sh

View

Short Volume

Short vol %

17%

As of: Jul 9, 2026

Short Total

View

Fails to Deliver

FTD shares

19.4K

Value: $68.1K
As of: Jun 11, 2026

View

Off-Exchange

Off-exchange %

42.4%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$65.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-74.9M

EPS diluted: $-1.18

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 25, 2026
This year: 10

View

Proposed Sales

Value

$65.0K

Shares: 18.0K
Filed: Jun 26, 2026

View

Exempt Offerings

Offering

$68.5M

Filed: Jun 11, 2020

View

Earnings & Events

Earnings Calls

Last call

Apr 27, 2026

View

Performance

	5D	20D	120D	MTD	YTD
FULC	+1.9%	+8.4%	-63.6%	+1.9%	-67.0%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+2.1%	+7.6%	-71.1%	+2.1%	-76.3%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance